Ep. 164 - Viehbacher’s Vision, NK Cells & Bat Biotech

BioCentury This Week

English - March 07, 2023 00:00 - 26 minutes - 18.4 MB - ★★★★★ - 11 ratings
Science biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Ep. 163 - EU Pharma Law Overhaul, Abortion Drug Ruling, Dunn's Departure

Next Episode: Ep. 165 - SVB Fallout, Plus: Pfizer-Seagen

On the latest episode of the BioCentury This Week podcast, BioCentury’s editors assess the challenges and opportunities facing Christopher Viehbacher as he begins to implement his vision for Biogen. The team also analyzes the state of play among NK cell therapy companies and discusses highlights from BioCentury’s Emerging Company Profile of Paratus Sciences Corp., a well-funded biotech being built around the idea that insights derived from the study of bat biology can be applied directly to human health and health security. This week’s podcast is sponsored by Jeito Capital.